KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Net Income - Minority (2018 - 2025)

Teva Pharmaceutical Industries' Net Income - Minority history spans 8 years, with the latest figure at -$4.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Net Income - Minority rose 42.86% year-over-year to -$4.0 million, compared with a TTM value of -$4.0 million through Dec 2025, up 42.86%, and an annual FY2025 reading of -$4.0 million, up 42.86% over the prior year.
  • Net Income - Minority for Q4 2025 was -$4.0 million at Teva Pharmaceutical Industries, roughly flat from -$4.0 million in the prior quarter.
  • The five-year high for Net Income - Minority was -$4.0 million in Q3 2025, with the low at -$987.0 million in Q2 2021.
  • Average Net Income - Minority over 5 years is -$529.5 million, with a median of -$638.0 million recorded in 2023.
  • Year-over-year, Net Income - Minority dropped 1.54% in 2021 and then surged 98.87% in 2024.
  • Tracing TEVA's Net Income - Minority over 5 years: stood at -$966.0 million in 2021, then rose by 17.81% to -$794.0 million in 2022, then increased by 21.91% to -$620.0 million in 2023, then surged by 98.87% to -$7.0 million in 2024, then soared by 42.86% to -$4.0 million in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Net Income - Minority are -$4.0 million (Q4 2025), -$4.0 million (Q3 2025), and -$7.0 million (Q2 2025).